IBDEI0H7 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7692,1,4,0)
 ;;=4^N02.6
 ;;^UTILITY(U,$J,358.3,7692,2)
 ;;=^5015517
 ;;^UTILITY(U,$J,358.3,7693,0)
 ;;=N02.7^^52^518^76
 ;;^UTILITY(U,$J,358.3,7693,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7693,1,3,0)
 ;;=3^Recurrent & perst hematur w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,7693,1,4,0)
 ;;=4^N02.7
 ;;^UTILITY(U,$J,358.3,7693,2)
 ;;=^5015518
 ;;^UTILITY(U,$J,358.3,7694,0)
 ;;=N02.8^^52^518^81
 ;;^UTILITY(U,$J,358.3,7694,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7694,1,3,0)
 ;;=3^Recurrent & perst hematur w/ oth morphologic changes
 ;;^UTILITY(U,$J,358.3,7694,1,4,0)
 ;;=4^N02.8
 ;;^UTILITY(U,$J,358.3,7694,2)
 ;;=^5015519
 ;;^UTILITY(U,$J,358.3,7695,0)
 ;;=N02.9^^52^518^82
 ;;^UTILITY(U,$J,358.3,7695,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7695,1,3,0)
 ;;=3^Recurrent & perst hematur w/ unsp morphologic changes
 ;;^UTILITY(U,$J,358.3,7695,1,4,0)
 ;;=4^N02.9
 ;;^UTILITY(U,$J,358.3,7695,2)
 ;;=^5015520
 ;;^UTILITY(U,$J,358.3,7696,0)
 ;;=N03.0^^52^518^18
 ;;^UTILITY(U,$J,358.3,7696,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7696,1,3,0)
 ;;=3^Chr nephritic syndrome w/ minor glomerular abnormality
 ;;^UTILITY(U,$J,358.3,7696,1,4,0)
 ;;=4^N03.0
 ;;^UTILITY(U,$J,358.3,7696,2)
 ;;=^5015521
 ;;^UTILITY(U,$J,358.3,7697,0)
 ;;=N03.1^^52^518^17
 ;;^UTILITY(U,$J,358.3,7697,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7697,1,3,0)
 ;;=3^Chr nephritic syndrome w/ focal & seg glomerular lesions
 ;;^UTILITY(U,$J,358.3,7697,1,4,0)
 ;;=4^N03.1
 ;;^UTILITY(U,$J,358.3,7697,2)
 ;;=^5015522
 ;;^UTILITY(U,$J,358.3,7698,0)
 ;;=N03.2^^52^518^14
 ;;^UTILITY(U,$J,358.3,7698,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7698,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,7698,1,4,0)
 ;;=4^N03.2
 ;;^UTILITY(U,$J,358.3,7698,2)
 ;;=^5015523
 ;;^UTILITY(U,$J,358.3,7699,0)
 ;;=N03.3^^52^518^15
 ;;^UTILITY(U,$J,358.3,7699,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7699,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,7699,1,4,0)
 ;;=4^N03.3
 ;;^UTILITY(U,$J,358.3,7699,2)
 ;;=^5015524
 ;;^UTILITY(U,$J,358.3,7700,0)
 ;;=N03.4^^52^518^13
 ;;^UTILITY(U,$J,358.3,7700,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7700,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,7700,1,4,0)
 ;;=4^N03.4
 ;;^UTILITY(U,$J,358.3,7700,2)
 ;;=^5015525
 ;;^UTILITY(U,$J,358.3,7701,0)
 ;;=N03.5^^52^518^16
 ;;^UTILITY(U,$J,358.3,7701,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7701,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,7701,1,4,0)
 ;;=4^N03.5
 ;;^UTILITY(U,$J,358.3,7701,2)
 ;;=^5015526
 ;;^UTILITY(U,$J,358.3,7702,0)
 ;;=N03.6^^52^518^11
 ;;^UTILITY(U,$J,358.3,7702,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7702,1,3,0)
 ;;=3^Chr nephritic syndrome w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,7702,1,4,0)
 ;;=4^N03.6
 ;;^UTILITY(U,$J,358.3,7702,2)
 ;;=^5015527
 ;;^UTILITY(U,$J,358.3,7703,0)
 ;;=N03.7^^52^518^12
 ;;^UTILITY(U,$J,358.3,7703,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7703,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,7703,1,4,0)
 ;;=4^N03.7
 ;;^UTILITY(U,$J,358.3,7703,2)
 ;;=^5015528
 ;;^UTILITY(U,$J,358.3,7704,0)
 ;;=N03.8^^52^518^19
 ;;^UTILITY(U,$J,358.3,7704,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7704,1,3,0)
 ;;=3^Chr nephritic syndrome w/ other morphologic changes
 ;;^UTILITY(U,$J,358.3,7704,1,4,0)
 ;;=4^N03.8
 ;;^UTILITY(U,$J,358.3,7704,2)
 ;;=^5015529
